Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To develop an automatic gout register from electronic health records (EHRs) data.
Methods: We analysed the EHR of all patients >18 years old from a tertiary academic hospital (2013-2022) based on six criteria: International Classification of Diseases 10 gout diagnosis, urate-lowering therapy prescription, monosodium urate crystals in joint aspiration and gout-related terms in problem lists, clinical or imaging reports. We assessed the positive and negative predictive value (PPV and NPV) of the query by chart reviews.
Results: Of 2 110 902 outpatients and inpatients, 10 289 had at least one criterion for gout. The combination of joint aspiration OR diagnostic in the problem list OR≥2 other criteria created a register of 5138 patients, with a PPV of 92.4% (95% CI 88.5% to 95.0%) and an NPV of 94.3% (95% CI 91.9% to 96.0%). PPV and NPV were similar among outpatients and inpatients. Incidence was 2.9 per 1000 person-year and dropped by 30% from the COVID-19 pandemic onward. Patients with gout were on average 71.2 years old (SD 14.9), mainly male (76.5%), overweight (69.5%) and polymorbid (mean number of comorbidities of 3, IQR 1-5). More than half (57.4%) had received a urate-lowering treatment, 6.7% had a gout that led to a hospitalisation or ≥2 flares within a year and 32.9% received a rheumatology consultation.
Conclusion: An automatic EHR-based gout register is feasible, valid and could be used to evaluate and improve gout management. Interestingly, the register uncovered a marked underdiagnosis or under-reporting of gout since the COVID-19 pandemic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11043720 | PMC |
| http://dx.doi.org/10.1136/rmdopen-2024-004120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.
Lancet Rheumatol
September 2025
Academic Rheumatology, University of Nottingham, Nottingham, UK.
Background: Allopurinol, the most prescribed urate-lowering drug, is a known cause of severe cutaneous adverse reactions. We aimed to develop and validate a model to assess the risk of allopurinol-induced severe cutaneous adverse reactions in adults newly prescribed allopurinol.
Methods: In this retrospective new-user cohort study, we developed and validated a prognostic model using primary care, hospitalisation, and mortality data extracted from the UK Clinical Practice Research Datalink (CPRD) primary care database, for the period Jan 1, 2001, to March 29, 2021.
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Lancet Diabetes Endocrinol
August 2025
Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
Background: Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus dulaglutide, also a GLP-1 receptor agonist, in patients with type 2 diabetes.
Methods: We conducted a 52-week, open-label, active-controlled, phase 3 trial at 52 hospitals in China.
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial.
Rheumatol Ther
August 2025
Department of Rheumatology and Immunology, Huashan Hospital, Fudan University, Shanghai, China.
Introduction: Firsekibart, an anti-interleukin (IL)-1β monoclonal antibody, has demonstrated more sustained control of gout flares compared with compound betamethasone in previous clinical studies. This study evaluated the efficacy and safety of firsekibart versus etoricoxib for the treatment of frequent gout flares.
Methods: In this phase 2, randomized, open-label, active-controlled, multicenter study (NCT05936268), adults with gout according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2015 criteria experiencing frequent flares (≥ 2 flares within 12 months pre-screening) were randomized (1:1) to receive either a single subcutaneous injection of firsekibart 200 mg, or once-daily oral etoricoxib 120 mg administered until pain remission or treatment intolerance for up to 8 days.
Quzhuo tongbi formula for reducing gout flare related to uric acid lowering treatment: Study protocol for a multiple-center, randomized, double-blind, placebo, parallel-controlled clinical trial.
PLoS One
July 2025
College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Introduction: Gout, a prevalent metabolic rheumatic disease, arises from the accumulation of monosodium urate (MSU) crystals in joints, directly associated with hyperuricemia. Long-term or lifelong urate-lowering therapy (ULT) stands as the primary management strategy. However, there is a significant risk of gout flares during ULT, and current methods have drawbacks, including side effects.
View Article and Find Full Text PDFSerum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis.
Front Pharmacol
June 2025
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Background: Elevated serum uric acid (SUA) is strongly associated with adverse clinical outcomes. Sodium-glucose-cotransporter-2 (SGLT2) inhibitors not only lower blood glucose levels but also reduce UA. However, comparative data on the SUA-lowering effects among different SGLT2 inhibitors remain sparse, hindering evidence-based drug selection.
View Article and Find Full Text PDF